CY2071B1 - Method of treating androgenic alopecia with 5-alpha reductase inhibitors - Google Patents

Method of treating androgenic alopecia with 5-alpha reductase inhibitors

Info

Publication number
CY2071B1
CY2071B1 CY9802071A CY9802071A CY2071B1 CY 2071 B1 CY2071 B1 CY 2071B1 CY 9802071 A CY9802071 A CY 9802071A CY 9802071 A CY9802071 A CY 9802071A CY 2071 B1 CY2071 B1 CY 2071B1
Authority
CY
Cyprus
Prior art keywords
androgenic alopecia
reductase inhibitors
alpha reductase
treating
treating androgenic
Prior art date
Application number
CY9802071A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26836279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2071(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/214,905 external-priority patent/US5547957A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CY2071B1 publication Critical patent/CY2071B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY9802071A 1993-10-15 1998-09-11 Method of treating androgenic alopecia with 5-alpha reductase inhibitors CY2071B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13852093A 1993-10-15 1993-10-15
US08/214,905 US5547957A (en) 1993-10-15 1994-03-17 Method of treating androgenic alopecia with 5-α reductase inhibitors
PCT/US1994/011507 WO1995010284A1 (en) 1993-10-15 1994-10-11 Method of treating androgenic alopecia with 5-alpha reductase inhibitors

Publications (1)

Publication Number Publication Date
CY2071B1 true CY2071B1 (en) 1998-09-11

Family

ID=26836279

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9802071A CY2071B1 (en) 1993-10-15 1998-09-11 Method of treating androgenic alopecia with 5-alpha reductase inhibitors

Country Status (28)

Country Link
US (3) US5824686A (bg)
EP (1) EP0724444B1 (bg)
JP (1) JP3058351B2 (bg)
CN (1) CN1096861C (bg)
AT (1) ATE156358T1 (bg)
BG (1) BG62756B1 (bg)
BR (1) BR9407824A (bg)
CA (1) CA2173457C (bg)
CY (1) CY2071B1 (bg)
CZ (1) CZ287104B6 (bg)
DE (1) DE69404854T2 (bg)
DK (1) DK0724444T3 (bg)
DZ (1) DZ1817A1 (bg)
ES (1) ES2105774T3 (bg)
FI (1) FI961632A (bg)
GR (1) GR3024375T3 (bg)
HR (1) HRP940673B1 (bg)
HU (1) HU227861B1 (bg)
IL (1) IL111293A (bg)
LV (1) LV12103B (bg)
MX (1) MXPA99002296A (bg)
NO (1) NO309927B1 (bg)
NZ (1) NZ275678A (bg)
PL (1) PL184930B1 (bg)
RO (1) RO116864B1 (bg)
SK (1) SK282352B6 (bg)
TW (1) TW382595B (bg)
WO (1) WO1995010284A1 (bg)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
NL1005445C2 (nl) * 1997-03-05 1998-09-21 Gho St Holding B V Werkwijze voor het vermenigvuldigen van haar.
US5935968A (en) * 1997-03-17 1999-08-10 Merck & Co., Inc. Methods for treating polycystic ovary syndrome
DE69822636T2 (de) 1997-07-29 2005-01-05 Sankyo Co., Ltd. Azasteroidverbindung zur behandlung von alopezie, hirsutismus und seborrhoe
US6348348B1 (en) * 1998-04-07 2002-02-19 The Carnegie Institution Of Washington Human hairless gene and protein
IL124764A0 (en) * 1998-06-04 1999-01-26 Univ Ben Gurion Topical composition for treatment of baldness
JP2002530332A (ja) 1998-11-20 2002-09-17 ザ ゼネラル ホスピタル コーポレーション 毛の成長を促進するためのピレスロイド化合物の使用
AU6087700A (en) * 1999-07-15 2001-02-05 Procter & Gamble Company, The Nitrogen-containing steroid compounds and their use to regulate hair growth
ES2158828B1 (es) * 2000-02-22 2002-03-16 Tobajas Maximo Gomez Metodo cosmetico para estimular el nacimiento y el crecimiento del cabello.
WO2002019974A1 (fr) * 2000-09-04 2002-03-14 Ravi Shrivastava Associations synergiques a base de plantes pour traiter la chute des cheveux
EP1262177B1 (en) * 2001-05-31 2006-08-23 Pfizer Products Inc. Medical use of thyromimetic compounds to treat hair loss and compositions
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
DE60313603T2 (de) 2002-04-24 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
FR2954124B1 (fr) * 2009-12-18 2012-04-06 Fabre Pierre Dermo Cosmetique Utilisation du 2,3-dihydroxypropyl dodecanoate pour le traitement de la seborrhee
EP2600822A2 (en) * 2010-08-05 2013-06-12 Legacy Healthcare Holding Ltd. Method for stimulating hair growth
WO2012099258A1 (ja) * 2011-01-21 2012-07-26 株式会社 イギス 脱毛症治療剤
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic
EP2757881A4 (en) * 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF
EP2703003A1 (en) 2012-08-31 2014-03-05 Probelte Biotecnologia S.L. A pomegranate extract and compositions containing pomegranate polyphenols for treating or preventing diseases or physiopathological conditions associated with an excessive gene expression and/or physiological activity of interleukin-6
HRP20211765T1 (hr) * 2017-06-16 2022-02-18 Capilli Med Gmbh Kompozicija za sprječavanje opadanja kose i za pospješivanje rasta kose
US11331300B2 (en) * 2017-12-22 2022-05-17 Richard Postrel Reversing baldness through follicle regeneration
EP3991734A4 (en) 2019-06-28 2023-03-01 Gurus BioPharm Inc. AGENT FOR ENHANCING HAIR GROWTH
FR3106058B1 (fr) * 2020-01-09 2022-01-07 Oreal Procédé de traitement cosmétique
CN113398263B (zh) * 2021-08-06 2022-11-11 广东巧巧生物科技有限公司 一种治疗脱发的洗发水

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4396615A (en) * 1981-06-24 1983-08-02 Duke University Method of treating androgen-related disorders
US4885289A (en) * 1983-12-12 1989-12-05 Breuer Miklos M Alteration of character of male beard growth
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
ZA851426B (en) 1984-02-27 1986-10-29 Merck & Co Inc 17 beta-n-monosubstituted carbamoyl-4-aza-5 alpha-androst-1-en-3-ones as 5 alpha reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
EP0285382B1 (en) * 1987-04-03 1994-04-13 Merck & Co. Inc. Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
US5228431A (en) * 1990-04-26 1993-07-20 Giarretto Ralph R Drug-free method for treatment of the scalp for therapeutic purposes
DK0542802T3 (da) * 1990-08-10 1996-07-22 Upjohn Co Stimulering af hårvækst med kaliumkanalåbnere og 5alfa-reduktase-inhibitorer
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
DE69329856D1 (de) * 1992-05-20 2001-02-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5407944A (en) * 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
US5438061A (en) * 1993-07-16 1995-08-01 Merck & Co., Inc. 7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
US5708001A (en) * 1993-12-17 1998-01-13 Glaxo Wellcome Inc. Substituted 6-azaandrostenones
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
US5512555A (en) * 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5777134A (en) * 1995-10-26 1998-07-07 Merck & Co., Inc. 4-oxa and 4-thia steriods
US5780437A (en) * 1995-12-14 1998-07-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5849764A (en) * 1995-12-14 1998-12-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
LV12103A (lv) 1998-08-20
PL316854A1 (en) 1997-02-17
FI961632A0 (fi) 1996-04-12
HUT74426A (en) 1996-12-30
CZ108196A3 (en) 1996-08-14
US5824686A (en) 1998-10-20
GR3024375T3 (en) 1997-11-28
CN1096861C (zh) 2002-12-25
DK0724444T3 (da) 1997-09-15
JP3058351B2 (ja) 2000-07-04
RO116864B1 (ro) 2001-07-30
DE69404854D1 (de) 1997-09-11
HRP940673A2 (en) 1997-02-28
HRP940673B1 (en) 2000-02-29
NO309927B1 (no) 2001-04-23
BG100510A (bg) 1996-11-29
LV12103B (en) 1998-10-20
IL111293A (en) 1998-08-16
BG62756B1 (bg) 2000-07-31
TW382595B (en) 2000-02-21
US5760046A (en) 1998-06-02
WO1995010284A1 (en) 1995-04-20
CA2173457C (en) 1999-03-23
EP0724444A1 (en) 1996-08-07
ATE156358T1 (de) 1997-08-15
NZ275678A (en) 1999-09-29
US5981543A (en) 1999-11-09
AU7974294A (en) 1995-05-04
NO961497D0 (no) 1996-04-15
MXPA99002296A (es) 2004-08-27
IL111293A0 (en) 1994-12-29
NO961497L (no) 1996-04-15
HU9600976D0 (en) 1996-06-28
PL184930B1 (pl) 2003-01-31
CZ287104B6 (en) 2000-09-13
JPH09505034A (ja) 1997-05-20
SK282352B6 (sk) 2002-01-07
SK44896A3 (en) 1997-03-05
EP0724444B1 (en) 1997-08-06
FI961632A (fi) 1996-04-12
DZ1817A1 (fr) 2002-02-17
DE69404854T2 (de) 1998-02-19
CN1137237A (zh) 1996-12-04
CA2173457A1 (en) 1995-04-20
BR9407824A (pt) 1997-05-06
AU688395B2 (en) 1998-03-12
HU227861B1 (en) 2012-05-02
ES2105774T3 (es) 1997-10-16

Similar Documents

Publication Publication Date Title
MY123960A (en) Method of treating androgenic alopecia with 5- alpha reductase inhibitors.
GR3024375T3 (en) Method of treating androgenic alopecia with 5-alpha reductase inhibitors
PL312961A1 (en) Amidine derivatives exhibiting activity of nitrogen oxide synthetase
GEP20094660B (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases
AU2210400A (en) Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
IL111357A0 (en) 16-substituted-4-aza-androstanes, their preparation and pharmaceutical compositions containing them
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
AU2838101A (en) Use of melatonin for treating androgenetic and diffuse alopecia
CA2157836A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
EP0748221A4 (en) 7-SUBSTITUTED-4-AZA-STEROID DERIVATIVES AS 5-ALPHA REDUCTASE INHIBITORS
EP0747048A3 (en) Diterpenes and flavonoids as 5-alpha-reductase inhibitors
UA18224A (uk) Спосіб лікуваhhя дерматозів
UA29236A (uk) Спосіб лікування пізніх гестозів